LC-MS/MS Method for LSD Microdose Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying lysergic acid diethylamide (LSD) and its metabolite 2,3-dihydro-3-hydroxy-2-oxo lysergide (O-H-LSD) in human plasma are inadequate for microdosing, particularly due to sensitivity limitations and complex extraction procedures, which hinder the establishment of pharmacokinetic data necessary for therapeutic dosing and drug monitoring.
Innovation Solution
A novel LC-MS/MS method that involves plasma protein precipitation with acetonitrile, followed by centrifugation and online dilution, allowing for rapid and sensitive analysis of LSD and O-H-LSD with reduced sample volume requirements, enabling high-throughput analysis and accurate quantification of low doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional extraction methods are used for LSD quantification, then the analysis can be performed, but the sensitivity is insufficient for microdoses and the procedure is complex
Solution Approach 1:
The patent extracts and removes plasma proteins from the sample using acetonitrile precipitation, separating the proteins from the analytes (LSD and O-H-LSD). This extraction step concentrates the analytes in the supernatant, enabling sensitive detection of microdoses while simplifying the overall procedure compared to conventional multi-step extractions.
Solution Approach 2:
The patent changes the physical-chemical parameters of the sample by adjusting pH to 9.0 and using specific mobile phase compositions (ammonium bicarbonate buffer with acetonitrile). These parameter modifications optimize the ionization and detection of LSD and O-H-LSD by LC-MS/MS, significantly improving sensitivity for microdose quantification.
2Productivity
If conventional LC-MS/MS methods are used, then analysis can be performed, but the analysis time is long and sample volume requirements are high
Solution Approach 1:
The patent segments the sample processing into distinct functional steps: protein precipitation with acetonitrile, centrifugation to separate supernatant from precipitate, and direct injection of the supernatant into the LC-MS/MS system. This segmentation enables rapid processing with minimal sample volume (50 μL plasma per sample), significantly reducing analysis time and increasing throughput.
Solution Approach 2:
The patent performs preliminary protein precipitation and centrifugation steps before LC-MS/MS analysis, preparing the sample in advance to remove interfering substances. This preliminary action simplifies the subsequent analysis and reduces total processing time while maintaining high sensitivity for microdose quantification.
3Measurement precision
If existing methods are used for microdose quantification, then low concentrations can be detected, but the methods are not validated for therapeutic drug monitoring
Solution Approach 1:
The patent incorporates quality control samples at multiple concentration levels (including microdose levels) and performs method validation according to regulatory guidelines (FDA/EMA). The validation process includes assessing accuracy, precision, linearity, and recovery, providing feedback that confirms the method's reliability for therapeutic drug monitoring of LSD microdoses.
Solution Approach 2:
The patent optimizes analytical parameters including mobile phase composition (ammonium bicarbonate buffer at pH 9.0), ionization mode (positive ionization for LSD, negative for O-H-LSD), and injection volume to achieve accurate quantification at microdose levels. These parameter optimizations, combined with proper validation, establish the method's reliability for therapeutic monitoring.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a sensitive and efficient means to quantify LSD and O-H-LSD in human plasma, facilitating the establishment of pharmacokinetic profiles for microdoses, supporting therapeutic dosing adjustments and drug monitoring, with improved sensitivity and reduced analysis time compared to existing methods.
Implementation Method 1
plasma protein precipitation with acetonitrile
Implementation Method 2
followed by centrifugation
Implementation Method 3
LC-MS/MS analysis
Implementation Method 4
LC-MS/MS analysis
Data Source
AI summary
A method of measuring and identifying LSD and its major metabolite O-H-LSD, by obtaining a sample from an individual, and measuring, identifying, and quantifying LSD and O-H-LSD in the sample by performing a LC-MS/MS analysis. A method of treating and monitoring individuals taking LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, monitoring the individual by obtaining a sample from an individual and measuring and identifying the analytes in the sample by performing a LC-MS/MS analysis, and adjusting the microdose based on the amount of LSD quantified in the LC-MS/MS analysis. A method of adjusting dosing of LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, and adjusting the microdose based on blood concentration analytics.